News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
43,526 Results
Type
Article (2696)
Company Profile (5)
Press Release (40816)
Multimedia
Podcasts (1)
Webinars (3)
Section
Business (9474)
Career Advice (267)
Deals (1185)
Drug Delivery (4)
Drug Development (6498)
Employer Resources (24)
FDA (1529)
Job Trends (1270)
News (19048)
Policy (2108)
Tag
Academia (325)
Accelerated approval (1)
Adcomms (3)
Allergies (6)
Alliances (3132)
ALS (14)
Alzheimer's disease (168)
Antibody-drug conjugate (ADC) (13)
Approvals (1565)
Artificial intelligence (58)
Autoimmune disease (4)
Automation (1)
Bankruptcy (9)
Best Places to Work (1243)
Biosimilars (27)
Biotechnology (7)
Bladder cancer (25)
Brain cancer (7)
Breast cancer (73)
Cancer (528)
Cardiovascular disease (31)
Career advice (242)
Career pathing (3)
CAR-T (11)
Cell therapy (35)
Cervical cancer (7)
Clinical research (5790)
Collaboration (97)
Compensation (6)
Complete response letters (5)
COVID-19 (185)
CRISPR (2)
C-suite (32)
Cystic fibrosis (10)
Data (687)
Denatured (1)
Depression (13)
Diabetes (41)
Diagnostics (320)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (30)
Drug pricing (2)
Duchenne muscular dystrophy (25)
Earnings (3800)
Editorial (4)
Employer branding (3)
Employer resources (22)
Events (7279)
Executive appointments (43)
FDA (1961)
Friedreich's ataxia (1)
Funding (58)
Gene editing (5)
Generative AI (4)
Gene therapy (54)
GLP-1 (55)
Government (350)
Guidances (33)
Healthcare (1445)
HIV (10)
Huntington's disease (6)
IgA nephropathy (11)
Immunology and inflammation (25)
Immuno-oncology (4)
Indications (13)
Infectious disease (193)
Inflammatory bowel disease (22)
Influenza (4)
Intellectual property (11)
Interviews (50)
IPO (659)
Job creations (102)
Job search strategy (201)
Kidney cancer (2)
Labor market (7)
Layoffs (15)
Leadership (5)
Legal (127)
Liver cancer (9)
Longevity (2)
Lung cancer (67)
Lymphoma (33)
Machine learning (7)
Management (11)
Manufacturing (28)
MASH (9)
Medical device (580)
Medtech (582)
Mergers & acquisitions (561)
Metabolic disorders (71)
Multiple sclerosis (5)
NASH (1)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (269)
NextGen: Class of 2025 (468)
Non-profit (375)
Obesity (23)
Opinion (32)
Ovarian cancer (22)
Pain (15)
Pancreatic cancer (13)
Parkinson's disease (14)
Partnered (5)
Patents (19)
Patient recruitment (31)
Peanut (4)
People (2413)
Pharmaceutical (3)
Phase I (1530)
Phase II (2188)
Phase III (2507)
Pipeline (448)
Policy (10)
Postmarket research (248)
Preclinical (715)
Press Release (1)
Prostate cancer (40)
Psychedelics (1)
Radiopharmaceuticals (13)
Rare diseases (81)
Real estate (219)
Recruiting (9)
Regulatory (2098)
Reports (5)
Research institute (246)
Resumes & cover letters (20)
Rett syndrome (10)
RNA editing (1)
RSV (2)
Schizophrenia (23)
Series A (11)
Series B (7)
Service/supplier (1)
Sickle cell disease (7)
Spinal muscular atrophy (8)
Sponsored (4)
Startups (173)
Stomach cancer (2)
Supply chain (6)
Tariffs (2)
Vaccines (37)
Venture capital (3)
Weight loss (6)
Women's health (2)
Worklife (5)
Date
Today (5)
Last 7 days (57)
Last 30 days (228)
Last 365 days (2561)
2025 (2465)
2024 (3015)
2023 (3408)
2022 (3907)
2021 (4090)
2020 (4026)
2019 (3680)
2018 (2712)
2017 (2082)
2016 (2009)
2015 (2225)
2014 (1426)
2013 (1083)
2012 (1167)
2011 (1327)
2010 (963)
Location
Africa (68)
Alabama (5)
Arizona (16)
Arkansas (1)
Asia (2384)
Australia (402)
California (823)
Canada (243)
China (60)
Colorado (11)
Connecticut (49)
Delaware (25)
Europe (5775)
Florida (111)
Georgia (18)
Idaho (8)
Illinois (41)
India (2)
Indiana (52)
Japan (41)
Kansas (9)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (112)
Massachusetts (746)
Michigan (10)
Minnesota (13)
Mississippi (1)
Missouri (6)
Montana (1)
Nebraska (4)
Nevada (25)
New Hampshire (4)
New Jersey (400)
New Mexico (1)
New York (266)
North Carolina (85)
Northern California (388)
Ohio (14)
Oregon (1)
Pennsylvania (145)
Rhode Island (1)
South America (79)
South Carolina (1)
Southern California (322)
Tennessee (10)
Texas (128)
United States (3253)
Utah (24)
Virginia (15)
Washington D.C. (13)
Washington State (152)
West Virginia (1)
Wisconsin (2)
43,526 Results for "akili interactive".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
Press Releases
Virtual Therapeutics Announces Results of Tender Offer to Acquire Akili Interactive
July 2, 2024
·
6 min read
Drug Development
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
February 27, 2024
·
10 min read
Business
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
Akili, Inc., a leading digital medicine company, reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress.
May 14, 2024
·
13 min read
Press Releases
BioCytics Successfully Completes a Key Regulatory Milestone with Recent FDA INTERACT Meeting
November 19, 2025
·
2 min read
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Genetown
Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD).
June 18, 2024
·
11 min read
Business
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress.
February 29, 2024
·
18 min read
Genetown
Akili Announces Business Transformation, Focusing on Non-prescription Model
Akili, Inc., a leading digital medicine company, announced its strategic plan to transition from a prescription to a non-prescription business model.
September 13, 2023
·
15 min read
Business
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
Akili, Inc., a leading digital medicine company, provided several corporate updates, including that it plans to report fourth quarter and full year 2023 financial results and a business update via press release on Thursday, February 29, 2024 after the market closes.
February 21, 2024
·
4 min read
1 of 4,353
Next
